Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024 - Report - MDSpire
Advertisement
Patterns of Treatment and Outcomes for Patients Diagnosed with Metastatic Pancreatic Adenocarcinoma in the United States, 2019–2024
Clinical Report: Patterns of Treatment and Outcomes for Patients Diagnosed with Metastatic Pancreatic Adenocarcinoma in the United States, 2019–2024
Overview
This study evaluates treatment patterns and outcomes for patients with metastatic pancreatic adenocarcinoma (mPAC) in the U.S. from 2019 to 2024.
Background
Pancreatic cancer is a leading cause of cancer-related mortality in the U.S., with a low 5-year survival rate of approximately 3% for metastatic cases. Understanding treatment patterns and outcomes is important given the limited therapeutic options available.
Data Highlights
Characteristic
FOLFIRINOX
Gem-Nab
Median Overall Survival
10.7 months
7.6 months
Median Time to Treatment Discontinuation
4.7 months
3.4 months
Percentage of Patients Not Receiving Therapy
33.5%
Key Findings
41.5% of patients received gemcitabine plus nab-paclitaxel (Gem-Nab) as first-line therapy.
36.3% of patients received FOLFIRINOX as first-line therapy.
Patients receiving FOLFIRINOX were generally younger and had better performance status.
Median overall survival was significantly longer for FOLFIRINOX compared to Gem-Nab (10.7 vs 7.6 months).
33.5% of patients did not initiate systemic therapy within 180 days of metastatic diagnosis.
Clinical and sociodemographic factors influenced the selection of first-line treatment regimens.
Clinical Implications
The findings indicate disparities in treatment initiation among patients with mPAC.
Conclusion
This study presents data on treatment initiation and survival outcomes in patients with mPAC.
